According to a new study by analysts at KPMG in conjunction with Canada’s pharmaceutical trade group Rx&D, there was 20% under-reporting of investment. Rx&D’s president, Russell Williams, says: “The report is clear and offers a more accurate picture of the contributions made by Rx&D members in Canada. With close to C$1.5 billion ($1.53 billion) investment in 2010, the report proves that Rx&D members are amongst the largest private sector investors in Health Research in this country and make a very important contribution to communities.”
He noted that the report demonstrates that the measurements used in the past did not capture the full extent and breadth of industry contributions to Canada and Canadians and, over the past few years, “the nature of pharmaceutical research and development activity has undergone significant change as research and business models have evolved, becoming more collaborative and global.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze